Dexamethasone palmitate-loaded sHDL nanodiscs: Enhanced efficacy and safety in allergic conjunctivitis
Year: 2025
Type: article
Abstract: Allergic conjunctivitis is a common ocular surface condition. Although corticosteroids are potent anti-inflammatory agents for its management, their use is often restricted by potential side effects. Conventional eye drops face challenges such as short retention time and poor corneal permeability, resulting in low drug bioavailability. To overcome these limitations, we developed a preservative-free synthetic high-density lipoprotein (sHDL) nanodisc eye drop containing dexamethasone palmitate. This novel formulation enhances drug stability and extends retention time on the ocular surface. In a mouse model of ovalbumin (OVA)-induced allergic conjunctivitis, the nanodisc eye drop significantly alleviated symptoms while reducing corticosteroid concentration, demonstrating excellent safety and biocompatibility. This innovative approach shows great promise for the treatment of allergic conjunctivitis and may lay the groundwork for new therapeutic strategies in anterior ocular disease management. • The residence time of synthetic high-density lipoprotein nanodisc eye drops on the ocular surface of mice is prolonged. • The synthetic high-density lipoprotein nanodisc eye drops exhibit superior permeability performance in vitro . • The synthetic high-density lipoprotein nanodisc eye drops reduce the concentration of corticosteroids during administration. • The synthetic lipoprotein nanodisc eye drops are free of preservatives, exhibiting high safety and minimal side effects.
Authors: Jiawei Li, Pengyue Liu, Yue Zhang, Fan Yang
Institutions: Sheng Jing Hospital, China Medical University
Language: English
Subfield: Pharmaceutical Science
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,950
OpenAlex ID: W4408673068